Rheumatoid Arthritis

Jeffrey Sparks, MD, MMSc, discusses what rheumatologists need to know about treating challenging cases of rheumatoid arthritis as well as the risks and benefits of more aggressive treatment strategies.

Patients receiving TNF, JAK, and CTLA4-Ig all demonstrated higher discontinuation rates due to ineffectiveness when compared to aIL-6R treatment.

In this MEDcast episode, Drs Soloman, Sharobeem, Boone and Feldman discuss the use of step therapy in rheumatoid arthritis, how step therapy was intended to be used, how it is actually used, and challenges and solutions to its use.

Although patients in both the intervention and control cohorts gained weight, patients treated with glucocorticoids gained an average of 1.1 kg more than controls.

The comprehensive score was able to recognize 119 high-risk participants (false positive rate of 29%) and 336 low-risk patients (false negative rate of 19%).

At months 6 and 12, tocilizumab retention rates were 94.1% and 86.6%, respectively.

The risk of mortality was significantly higher in patients with RA treated with JAKs who had not received the COVID-19 vaccine.

No statistically significant differences in retention rates were observed among those treated with baricitinib monotherapy or in combination with methotrexate.

Improvements in CDAI by >5 points were associated with improvements in the 5 PROMIS domains and increased satisfaction with rheumatoid arthritis treatment.

Results found all clinical and patient-reported responses were statistically better with upadacitinib plus methotrexate compared with adalimumab plus methotrexate, although both treatments were effective.

In this episode of Relatable Rheumatology, experts discuss a critically important topic for patients with rheumatoid arthritis: bloodwork and laboratory tests.

An analysis of the ORAL Surveillance trial details the efficacy of tofacitinib relative to TNF inhibition based on history of ASCVD and baseline cardiovascular risk.

Noortje van Herwaarden, MD, PhD, discusses the results of a 10-year follow-up from the DRESS study and how it informs use of disease activity-guided dose optimization in treatment of rheumatoid arthritis.

George Karpouzas, MD, discusses the results of a study he presented at EULAR 2023 examining associations between bDMARD use and cardiovascular risk later in life.

An analysis of patient data from Sweden and Norway detail the impact of achieving remission with methotrexate or TNF inhibitors on risk of acute coronary syndrome in patients with rheumatoid arthritis.

In today’s episode, we explore how the lived experience of someone with rheumatoid arthritis can systematically be documented via the use of patient-reported outcome measures.

At the 12-week mark, the change from baseline in the DAS28-CRP was significantly greater in patients with rheumatoid arthritis receiving 700 mg peresolimab when compared with the placebo group.

Results highlight the need for physicians to consider rheumatoid arthritis in patients with microscopic colitis presenting with arthralgia or other joint symptoms.

A comparison of monotherapy biologic or targeted synthetic DMARDs initiated in naive patients show each are beneficial for rheumatoid arthritis.

A maternal rheumatoid arthritis (RA) diagnosis before delivery was linked to an increased risk of offspring with autism spectrum disorder, particularly for those with seronegative RA.

The use of traditional Chinese medicine had a statistically significant association with improved clinical indicators in patients with rheumatoid arthritis.

Patients with “good health literacy” had significantly lower disease activity over time than those with “several health literacy limitations,” adjusting for age, gender and education level.

GPX3, an antioxidant enzyme and reactive oxygen species scavenger, was categorized as a hub gene in rheumatoid arthritis neutrophils.

Women with rheumatoid arthritis (RA) in remission exhibited higher values of Disease Activity Score-28 for Rheumatoid Arthritis with erythrocyte sedimentation rate (DAS28-ESR) compared with men.

At month 6, 71.0% in the smart system of disease management group achieved a DAS28-CRP of 3.2 or less compared with 64.5% in the control group.